Global trial ends 20-year debate over gastro-esophageal cancer treatment
15 September 2024
Cancer patients could avoid unnecessary radiation therapy as a result of an international clinical trial led by Peter Mac researcher Prof Trevor Leong.
The TOPGEAR study demonstrated that radiotherapy does not improve survival outcomes for patients with operable gastric and gastro-esophageal junction cancer when compared to chemotherapy alone.
The trial results were presented at the European Society for Medical Oncology (ESMO) Congress 2024 and published simultaneously in the New England Journal of Medicine.
More than 2,500 Australians are diagnosed with stomach cancer each year and the study investigated whether adding radiotherapy to the treatment approach of surgery plus chemotherapy would improve outcomes for patients.
All trial participants had chemotherapy before and after surgery – the ‘standard of care’ in most countries – while some were randomised to also have radiotherapy before surgery.
Prof Leong says there has been a 20-year debate over the role of radiotherapy in treating these cancers, after earlier studies suggested a benefit of radiotherapy after surgery.
“Our results now demonstrate that even when delivered optimally as preoperative therapy, radiotherapy does not improve survival outcomes compared to chemotherapy alone,” says Professor Leong.
“The TOPGEAR trial results have the potential to be practice changing as some centres around the world, particularly in the USA, currently employ preoperative radiotherapy as standard treatment for gastric cancer.
“Preoperative radiotherapy is also a standard of care treatment for patients with gastro-esophageal junction cancers, who comprised one third of the TOPGEAR patient cohort,” he said.
TOPGEAR started at Peter Mac in 2009 and opened to patients internationally from 2014 with 70 sites across 15 countries taking part.
Professor Leong, from Peter Mac's Department of Radiation Oncology, presented the results at a plenary session at ESMO Congress 2024 in Barcelona.
Preoperative radiotherapy was seen to improve the rate of pathological complete response – meaning the cancer became undetectable – in trial participants, at 17% compared to 8% for the chemotherapy plus surgery approach.
However, at follow-up some five years later (median 67 months), there was no significant difference between these groups in progression-free and overall survival.
“While the increase in pathological complete response is interesting and may warrant further investigation, in the longer term radiotherapy did not meaningfully improve cancer control or extend lives,” Professor Leong says.
Professor Leong notes as patients must attend their specialist cancer centre multiple times to complete their radiotherapy, ceasing this requirement would reduce the overall burden of treatment for these patients.
TOPGEAR was an international, intergroup collaboration led by the Australasian Gastro-Intestinal Trials Group (AGITG) and the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, in collaboration with the Trans-Tasman Radiation Oncology Group (TROG), European Organisation for Research and Treatment of Cancer (EORTC), and the Canadian Cancer Trials Group (CCTG).
As an academic (non-industry sponsored) trial, TOPGEAR was funded by three successive NHMRC grants and others. The NEJM paper is titled “Preoperative Chemoradiotherapy for Resectable Gastric Cancer” - Read it in full here.
< ends >
Contacts:
For more information contact the Peter Mac Communications team on 0417 123 048.
About Peter Mac
Peter MacCallum Cancer Centre is a world leading cancer research, education and treatment centre and Australia’s only public health service dedicated to caring for people affected by cancer.